42 results on '"Mauskopf J"'
Search Results
2. Alzheimer's disease: The strength of association of costs with different measures of disease severity
3. Patient preferences for acute pain treatment
4. HTA176 A Systematic Literature Review of Rationale, Methods, and Use of Cost-Effectiveness Thresholds in Health Technology Assessments
5. EE184 Assessing the Cost-Effectiveness of the Novavax COVID-19 Vaccine as a Potential Booster Vaccine Option for Adults in the United States
6. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast
7. PNS28 CHALLENGES IN ESTIMATING ELIGIBLE POPULATION SIZE IN BUDGET-IMPACT ANALYSES FOR NEW HEALTH CARE TECHNOLOGIES
8. PND15 THE VARIABILITY IN STRUCTURAL ASSUMPTIONS IN MODELS ESTIMATING THE EFFECTIVENESS OF HYPOTHETICAL DISEASE MODIFYING TREATMENT FOR ALZHEIMER'S DISEASE
9. Budget-Impact Analysis
10. PHP36 - US Payer Perspectives on Value and Comparisons Outside The US: An Interview Study
11. PMD27 - Do Budget Impact Analyses For Screening Of Cancers Follow International Guidelines? A Systematic Review
12. PSU36 Evidence Based Medicine: A Case Study of its Application to Innovative Surgical Procedures in the UK
13. PIN18 Rates of Influenza Complications by High Risk Group
14. PHP125 An Early Assessment of the German Federal Joint Commission Resolutions of Additional Clinical Benefit
15. PHP112 Estimating the Probability of a Favorable Assessment of Clinical Benefits for a New Drug in Germany Using an MCDA Approach
16. PP071-SUN IMMUNONUTRITION FOR GASTROINTESTINAL CANCER PATIENTS: AN EFFECTIVE AND COST-SAVINGS INTERVENTION
17. PHP116 Clincal and Economic Evidence Bases for Health Technology Assessment: A Comparison of Three Jurisdictions
18. PHP64 THE RELATIONSHIP BETWEEN FINANCIAL IMPACT AND THE LIKELIHOOD OF DRUG REIMBURSEMENT IN THE AUSTRALIAN HEALTH CARE SYSTEM
19. CE4 USING DYNAMIC TRANSMISSION MODELS TO ESTIMATE THE COST EFFECTIVENESS OF VACCINES: FOUR DIFFERENT METHODS AND THEIR RELEVANCE FOR DECISION MAKERS
20. PIH16 COST-EFFECTIVENESS ANALYSIS FOR TREATMENT OF SYMPTOMATIC UTERINE FIBROIDS AMONG PREMENOPAUSAL WOMEN SEEKING TO RETAIN UTERUS
21. PMH48 VALIDATING A COST-EFFECTIVENESS ANALYSIS COMPARING OLANZAPINE WITH ZIPRASIDONE IN THE TREATMENT OF SCHIZOPHRENIA
22. PMC31 THE ROLE OF THE PATIENT VOICE IN HEALTH TECHNOLOGY ASSESSMENT
23. PCV56 IMPACT OF INCLUDING PRASUGREL ON THE FORMULARY FOR PATIENTS WHO UNDERGO PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROME
24. PCV41 ADHERENCE TO GUIDELINES FOR SENSITIVITY ANALYSIS: COSTEFFECTIVENESS ANALYSES OF DUAL ORAL ANTIPLATELET THERAPY
25. 25 – Development of a cost-effectiveness model for evaluating treatment of acute mania/mixed mania in bipolar I disorder
26. PIN14 A CANADIAN COST-EFFECTIVENESS ANALYSIS OF DARUNAVIR FOR HIV INFECTION IN TREATMENTEXPERIENCED ADULTS
27. IN1 COST-EFFECTIVENESS ANALYSIS OF DARUNAVIR/R FOR HIV INFECTION IN TREATMENT-EXPERIENCED ADULTS IN THE US: UNDERSTANDING THE UNCERTAINTY IN THE ESTIMATES
28. ES2/PMH44 COSTS AND OUTCOMES OF ATYPICAL ANTIPSYCHOTICS FOR THE TREATMENT OF ACUTE SCHIZOPHRENIA
29. PMH48 MEASUREMENT OF UTILITY LOSSES IN DEPRESSION
30. PMC3 HOW MUCH DOES A DAY IN THE HOSPITAL COSTÏ
31. Budget model for estimating economic impact of fluticasone propionate/salmeterol via Diskus® in an adult asthma population
32. PCHI I: ESTIMATING THE BUDGET AND HEALTH IMPACTS OF LETROZOLE FOR ADVANCED BREAST CANCER
33. PMD14 WILLINGNESS TO PAY, WILLINGNESS TO WAIT, AND SUPER QALYS: NARROWING THE CONCEPTUAL GAP BETWEEN CARDINAL AND ORDINAL HEALTH UTILITY MEASURES
34. PNM25 DRUG PERSISTENCE PATTERNS SIMILAR FOR RIVASTIGMINE-TREATED PATIENTS AND DONEPEZIL-TREATED PATIENTS
35. PMI13 STANDARD GAMBLE AND CONJOINT UTILITY WEIGHTS: VALIDITY, FEASIBILITY, AND USEFULNESS
36. DS3: DESIGN AND ANALYSIS OF UNIT COST ESTIMATION STUDIES: HOW MANY TYPES OF HOSPITALIZATION? HOW MANY COUNTRIES?
37. PMH25: A MODEL COMPARING OLANZAPINE AND ZIPRASIDONE IN PATIENTS WITH SCHIZOPHRENIA
38. WPE7: SCHIZOPHRENIA: HELPING THE DECISIONMAKER TO UNDERSTAND THE IMPACTS OF ATYPICAL ANTIPSYCHOTICS
39. Ionic requirements for the active ileal bile salt transport system
40. Interaction of uncharged bile salt derivatives with the ileal bile salt transport system
41. CM1 Estimating the Costs And Outcomes for Different Disease Management Strategies: A Case Study of Cyomegalovirus Infection And Disease
42. ID4 Evaluation of the Cost-Effectiveness of Management Strategies in Cytomegalovirus Infection And Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.